SAN MATEO, Calif., Jan. 11, 2021 /PRNewswire/ — Rakuten Medical, Inc. (Rakuten Medical) today announced the acquisition of phthalocyanine dyes, including IRDye^® 700DX, from LI-COR Biosciences. IRDye 700DX is a key component of the mechanism of action for products being developed by Rakuten Medical, and is currently being studied in ASP-1929 clinical trials across multiple oncology indications. This strategic acquisition ensures a consistent and flexible supply chain to further advance development and commercialization of therapies on the Illuminox™ platform, such as ASP-1929 and other photoimmunotherapy products. Read more here…